Metabolism Altered Convulsive Effects Differently for Two Synthetic Cannabinoids

Two synthetic cannabinoids did not respond identically to a metabolic inhibitor in a mouse experiment. The difference is a reason to avoid treating every synthetic cannabinoid as pharmacologically interchangeable.

The study compared specific compounds

Researchers scored observed convulsive effects of JWH-018 and 5F-AB-PINACA, with THC and pentylenetetrazole included as comparisons. THC did not elicit convulsions in the reported conditions, whereas the two synthetic agonists did. That is an observation about this experiment, not a universal statement about all exposures.

Metabolic inhibition produced a selective finding

Nonselective CYP450 inhibition protected against the convulsive effects of JWH-018 but not those of 5F-AB-PINACA or pentylenetetrazole. Human liver-microsome work also showed a difference in oxidative elimination between the two synthetic cannabinoids.

Receptor and metabolism evidence answer different questions

Rimonabant and selected cannabinoid pretreatments attenuated the synthetic-cannabinoid effects without changing the pentylenetetrazole effects. The findings support receptor involvement while showing that metabolism can modify the outcome for one compound more than another.

The behavioral rating does not itself establish an EEG-confirmed seizure. The microsome experiments are laboratory metabolism studies, not measurements of concentrations in an affected patient. The reported diazepam findings should not be used to dictate emergency treatment in people. A clinical or forensic interpretation requires the actual substance and observed syndrome rather than a generic label such as Spice or cannabis.

Related: interpreting cannabis tolerance claims.

Research cited

Wilson CD; Tai S; Ewing L; Crane J; Lockhart T; Fujiwara R; Radominska-Pandya A; Fantegrossi WE. Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. The Journal of pharmacology and experimental therapeutics (2019). doi:10.1124/jpet.118.251157. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us